{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T23:16:20Z","timestamp":1780528580103,"version":"3.54.1"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,29]],"date-time":"2023-04-29T00:00:00Z","timestamp":1682726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Chinese Journal of Traumatology"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.cjtee.2023.04.006","type":"journal-article","created":{"date-parts":[[2023,5,2]],"date-time":"2023-05-02T01:42:10Z","timestamp":1682991730000},"page":"297-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Why anticoagulant studies on sepsis fail frequently --- start with SCARLET"],"prefix":"10.1016","volume":"26","author":[{"given":"Jian-Ying","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yuan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjtee.2023.04.006_bib1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/bjh.17172","article-title":"Disseminated intravascular coagulation: epidemiology, biomarkers, and management","volume":"192","author":"Adelborg","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cjtee.2023.04.006_bib2","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross talk pathways between coagulation and inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ Res"},{"key":"10.1016\/j.cjtee.2023.04.006_bib3","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2019.5358","article-title":"Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: the SCARLET randomized clinical trial","volume":"321","author":"Vincent","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.cjtee.2023.04.006_bib4","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1097\/CCM.0b013e31828e9b03","article-title":"A\u00a0randomized, double-blind, placebo-controlled, phase 2b study to evaluate the safety and efficacy of recombinant human soluble thrombomodulin, ART-123, in patients with sepsis and suspected disseminated intravascular coagulation","volume":"41","author":"Vincent","year":"2013","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cjtee.2023.04.006_bib5","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1111\/j.1538-7836.2004.00955.x","article-title":"Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation","volume":"2","author":"Dhainaut","year":"2004","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.cjtee.2023.04.006_bib6","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1001\/jama.286.15.1869","article-title":"Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial","volume":"286","author":"Warren","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cjtee.2023.04.006_bib7","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.cjtee.2023.04.006_bib8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1055\/s-0038-1676345","article-title":"Recombinant human soluble thrombomodulin in sepsis-induced coagulopathy: an updated systematic review and meta-analysis","volume":"119","author":"Yamakawa","year":"2019","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.cjtee.2023.04.006_bib9","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13054-019-2587-2","article-title":"Recombinant human soluble thrombomodulin in patients with sepsis-associated coagulopathy (SCARLET): an updated meta-analysis","volume":"23","author":"Yamakawa","year":"2019","journal-title":"Crit Care"},{"key":"10.1016\/j.cjtee.2023.04.006_bib10","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/CCM.0000000000004426","article-title":"Effect of a Recombinant human soluble thrombomodulin on baseline coagulation biomarker levels and mortality outcome in patients with sepsis-associated coagulopathy","volume":"48","author":"Levi","year":"2020","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cjtee.2023.04.006_bib11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1186\/cc13971","article-title":"Is early treatment of disseminated intravascular coagulation beneficial in septic patients?","volume":"18","author":"Wada","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.cjtee.2023.04.006_bib12","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelman","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.cjtee.2023.04.006_bib13","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/rth2.12109","article-title":"The coagulation system in host defense","volume":"2","author":"Antoniak","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.cjtee.2023.04.006_bib14","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/cc12783","article-title":"A\u00a0multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis","volume":"17","author":"Gando","year":"2013","journal-title":"Crit Care"},{"key":"10.1016\/j.cjtee.2023.04.006_bib15","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1111\/jth.14590","article-title":"Managing sepsis-associated coagulopathy remains an enigma","volume":"17","author":"Thachil","year":"2019","journal-title":"J\u00a0Thromb Haemostasis"},{"key":"10.1016\/j.cjtee.2023.04.006_bib16","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13613-021-00842-4","article-title":"Efficacy and safety of human soluble thrombomodulin (ART-123) for treatment of patients in France with sepsis-associated coagulopathy: post hoc analysis of SCARLET","volume":"11","author":"Fran\u00e7ois","year":"2021","journal-title":"Ann Intensive Care"},{"key":"10.1016\/j.cjtee.2023.04.006_bib17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1160\/TH05-07-0530","article-title":"Benefit\/risk profile of high-dose antithrombin in patients with severe sepsis treated with and without concomitant heparin","volume":"95","author":"Hoffmann","year":"2006","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.cjtee.2023.04.006_bib18","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1097\/01.CCM.0000194731.08896.99","article-title":"High-dose antithrombin III in the treatment of severe sepsis in patients with a high risk of death: ef\ufb01cacy and safety","volume":"34","author":"Wiedermann","year":"2006","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cjtee.2023.04.006_bib19","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1056\/NEJMoa050935","article-title":"Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death","volume":"353","author":"Abraham","year":"2005","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjtee.2023.04.006_bib20","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0140-6736(07)60411-5","article-title":"Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase \u2162 randomized controlled trail","volume":"369","author":"Nadel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cjtee.2023.04.006_bib21","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjtee.2023.04.006_bib22","series-title":"Activated protein C and sepsis: The debate remains. In: Chinese Medical Association. Yearbook of Critical Care Medicine 2013","first-page":"93","author":"Deng","year":"2013"},{"key":"10.1016\/j.cjtee.2023.04.006_bib23","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1186\/s13054-014-0563-4","article-title":"Heparin therapy reduces 28-day mortality in adult severe sepsis patients: a systematic review and meta-analysis","volume":"18","author":"Wang","year":"2014","journal-title":"Crit Care"},{"key":"10.1016\/j.cjtee.2023.04.006_bib24","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CCM.0000000000000763","article-title":"The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis","volume":"43","author":"Zarychanski","year":"2015","journal-title":"Crit Care Med"},{"key":"10.1016\/j.cjtee.2023.04.006_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12871-021-01545-w","article-title":"Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis","volume":"22","author":"Fu","year":"2022","journal-title":"BMC Anesthesiol"},{"key":"10.1016\/j.cjtee.2023.04.006_bib26","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1164\/rccm.200612-1803OC","article-title":"Prophylactic heparin in patients with severe sepsis treated with drotrecogin alfa (activated)","volume":"176","author":"Levi","year":"2007","journal-title":"Am J Respir Crit Care Med"}],"container-title":["Chinese Journal of Traumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1008127523000421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1008127523000421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T14:17:36Z","timestamp":1760883456000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1008127523000421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S1008127523000421"],"URL":"https:\/\/doi.org\/10.1016\/j.cjtee.2023.04.006","relation":{},"ISSN":["1008-1275"],"issn-type":[{"value":"1008-1275","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Why anticoagulant studies on sepsis fail frequently --- start with SCARLET","name":"articletitle","label":"Article Title"},{"value":"Chinese Journal of Traumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjtee.2023.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Production and hosting by Elsevier B.V. on behalf of Chinese Medical Association.","name":"copyright","label":"Copyright"}]}}